ADA Scientific Sessions 2026 Abstract

Is Polycythemia Part of the Causal Pathway between SGLT2i and Peripheral Artery Disease and Amputation Events?

By Aidar R. Gosmanov, Cole Beck, Amber J. Hackstadt, Christianne L. Roumie

Study in peopleMechanisms

The paper

Aidar R. Gosmanov, Cole Beck, Amber J. Hackstadt, Christianne L. Roumie

Albany

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, poster 2194-P

doi.org/10.2337/db26-2194-p

Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk